883 related articles for article (PubMed ID: 25798726)
1. Nivolumab: targeting PD-1 to bolster antitumor immunity.
Brahmer JR; Hammers H; Lipson EJ
Future Oncol; 2015; 11(9):1307-26. PubMed ID: 25798726
[TBL] [Abstract][Full Text] [Related]
2. PD-1 Pathway Inhibitors: Immuno-Oncology Agents for Restoring Antitumor Immune Responses.
Medina PJ; Adams VR
Pharmacotherapy; 2016 Mar; 36(3):317-34. PubMed ID: 26822752
[TBL] [Abstract][Full Text] [Related]
3. Nivolumab for the treatment of cancer.
Gunturi A; McDermott DF
Expert Opin Investig Drugs; 2015 Feb; 24(2):253-60. PubMed ID: 25494679
[TBL] [Abstract][Full Text] [Related]
4. The 'nivolution' in renal cell carcinoma: behind the scenes of clinical trials.
Buti S; Bersanelli M
Future Oncol; 2016 Sep; 12(18):2061-3. PubMed ID: 27168416
[No Abstract] [Full Text] [Related]
5. Nivolumab: A Review in Advanced Melanoma.
Scott LJ
Drugs; 2015 Aug; 75(12):1413-24. PubMed ID: 26220912
[TBL] [Abstract][Full Text] [Related]
6. The safety of nivolumab for the treatment of advanced non-small cell lung cancer.
Metro G; Ricciuti B; Brambilla M; Baglivo S; Soli I; Minenza E; Leonardi GC; D'arpino A; Colabrese D; Tazza M; Zicari D; Minotti V; Chiari R
Expert Opin Drug Saf; 2017 Jan; 16(1):101-109. PubMed ID: 27910704
[TBL] [Abstract][Full Text] [Related]
7. The evolution of checkpoint blockade as a cancer therapy: what's here, what's next?
Shin DS; Ribas A
Curr Opin Immunol; 2015 Apr; 33():23-35. PubMed ID: 25621841
[TBL] [Abstract][Full Text] [Related]
8. Immune Checkpoint Therapy in Renal Cell Carcinoma.
Lee CH; Motzer RJ
Cancer J; 2016; 22(2):92-5. PubMed ID: 27111903
[TBL] [Abstract][Full Text] [Related]
9. Clinical evaluation of compounds targeting PD-1/PD-L1 pathway for cancer immunotherapy.
Lu J; Lee-Gabel L; Nadeau MC; Ferencz TM; Soefje SA
J Oncol Pharm Pract; 2015 Dec; 21(6):451-67. PubMed ID: 24917416
[TBL] [Abstract][Full Text] [Related]
10. Nivolumab: A Review in Advanced Nonsquamous Non-Small Cell Lung Cancer.
Keating GM
Drugs; 2016 Jun; 76(9):969-78. PubMed ID: 27189706
[TBL] [Abstract][Full Text] [Related]
11. Nivolumab in renal cell carcinoma.
Michel Ortega RM; Drabkin HA
Expert Opin Biol Ther; 2015 Jul; 15(7):1049-60. PubMed ID: 26038957
[TBL] [Abstract][Full Text] [Related]
12. Nivolumab in previously untreated melanoma without BRAF mutation.
Robert C; Long GV; Brady B; Dutriaux C; Maio M; Mortier L; Hassel JC; Rutkowski P; McNeil C; Kalinka-Warzocha E; Savage KJ; Hernberg MM; Lebbé C; Charles J; Mihalcioiu C; Chiarion-Sileni V; Mauch C; Cognetti F; Arance A; Schmidt H; Schadendorf D; Gogas H; Lundgren-Eriksson L; Horak C; Sharkey B; Waxman IM; Atkinson V; Ascierto PA
N Engl J Med; 2015 Jan; 372(4):320-30. PubMed ID: 25399552
[TBL] [Abstract][Full Text] [Related]
13. Nivolumab: a review in advanced squamous non-small cell lung cancer.
Keating GM
Drugs; 2015 Nov; 75(16):1925-34. PubMed ID: 26514815
[TBL] [Abstract][Full Text] [Related]
14. Nivolumab.
Fulchiero E; Jimeno A
Drugs Today (Barc); 2014 Dec; 50(12):791-802. PubMed ID: 25588084
[TBL] [Abstract][Full Text] [Related]
15. Nivolumab for treating non-small cell lung cancer.
Guibert N; Mazières J
Expert Opin Biol Ther; 2015; 15(12):1789-97. PubMed ID: 26574148
[TBL] [Abstract][Full Text] [Related]
16. PD-1/PD-L1 inhibitors.
Sunshine J; Taube JM
Curr Opin Pharmacol; 2015 Aug; 23():32-8. PubMed ID: 26047524
[TBL] [Abstract][Full Text] [Related]
17. Atypical responses in patients with advanced melanoma, lung cancer, renal-cell carcinoma and other solid tumors treated with anti-PD-1 drugs: A systematic review.
Queirolo P; Spagnolo F
Cancer Treat Rev; 2017 Sep; 59():71-78. PubMed ID: 28756306
[TBL] [Abstract][Full Text] [Related]
18. Safety, activity, and immune correlates of anti-PD-1 antibody in cancer.
Topalian SL; Hodi FS; Brahmer JR; Gettinger SN; Smith DC; McDermott DF; Powderly JD; Carvajal RD; Sosman JA; Atkins MB; Leming PD; Spigel DR; Antonia SJ; Horn L; Drake CG; Pardoll DM; Chen L; Sharfman WH; Anders RA; Taube JM; McMiller TL; Xu H; Korman AJ; Jure-Kunkel M; Agrawal S; McDonald D; Kollia GD; Gupta A; Wigginton JM; Sznol M
N Engl J Med; 2012 Jun; 366(26):2443-54. PubMed ID: 22658127
[TBL] [Abstract][Full Text] [Related]
19. Differential Activity of Nivolumab, Pembrolizumab and MPDL3280A according to the Tumor Expression of Programmed Death-Ligand-1 (PD-L1): Sensitivity Analysis of Trials in Melanoma, Lung and Genitourinary Cancers.
Carbognin L; Pilotto S; Milella M; Vaccaro V; Brunelli M; Caliò A; Cuppone F; Sperduti I; Giannarelli D; Chilosi M; Bronte V; Scarpa A; Bria E; Tortora G
PLoS One; 2015; 10(6):e0130142. PubMed ID: 26086854
[TBL] [Abstract][Full Text] [Related]
20. PD-1 Blockers.
Wolchok JD
Cell; 2015 Aug; 162(5):937. PubMed ID: 26317459
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
